PCR 2013: A Focus on Sales Growth

NEW YORK, Aug. 13, 2013 /PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue:

PCR 2013: A Focus on Sales Growth
http://www.reportlinker.com/p0980750/PCR-2013-A-Focus-on-Sales-Growth.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=Genomics

Summary: This market analysis was carried out to provide business information to developers, manufacturers and suppliers in the PCR field. Its findings include:

- Marketing and sales opportunities
- End-user purchasing decisions
- Market growth and shrinkage
- Innovation and new product opportunities
This study was conducted through specialist groups of experienced PCR end-users and its findings are therefore based on 'real world' market data.

Market Analysis and Opportunities

A competitive market analysis of current practices and future developments across 25 key market areas in the PCR field. Examples include:
- PCR Techniques: Which PCR techniques are the market leaders and what changes do end-users predict over the next three years. Which PCR techniques are growing and which are reducing?
- PCR Applications: Which PCR applications are the market leaders and what changes do end-users predict over the next three years. Which PCR applications are growing and which are reducing?
- Suppliers: Who are the major company suppliers in the PCR field and who do PCR end-users plan to purchase from over the next three years. Who are the top ten suppliers in this field, and what changes are predicted in three years from now.
- Opportunities: The findings of this study are analysed to identify opportunities to suppliers in the PCR field, in the 'Market Areas' indicated below.
Overview
This market study was carried out to assist developers, manufacturers and suppliers in the PCR field, in marketing and sales. It was conducted through specialist groups of experienced clinical and laboratory PCR end-users, and its findings are based on 'real word' market data. By working closely with PCR experts, we were able to identify current and emerging commercial opportunities in this growing market.
The numbers of applications for PCR are considerable and include sequencing, genetic fingerprinting, cloning, disease research, diagnostics, drug discovery, biomarkers, forensics, the detection of viral and bacterial infections and many others. Such has been the impact of this technique that some observers have referred to two epochs in the life science field – "Before PCR" and "After PCR". As a technique, PCR offers many practical advantages, and developments in computing and software support new applications, and increase the volumes of biological information these methods can generate. Bucking current economic trends, PCR is growing by more than 13% per year and some estimates suggest that by 2015, global markets for this technique will exceed $27 billion.
Biopharm Reports has carried out a global market study of PCR, which investigated the use of this technique across more than fifteen different industrial/research fields. This involved the participation of 733 PCR end-users in 84 countries and was carried out to identify market developments and growth areas and the opportunities these offer to developers and vendors in this field.
With a focus on sales growth, this study investigated current and future techniques and applications, PCR suppliers, end-users' plans for using PCR over the next three years, as well as the PCR companies they anticipate purchasing from. Other market areas included preferred PCR systems, new developments, emerging applications, the strengths and weaknesses of current systems, innovation, budgets and expenditure, consumables, software, sample preparation and other areas. Further details are presented below.

Market Areas

- Current use of PCR: Use of PCR by end-users for running routine (developed and validated) PCR tests, the development or validation of PCR tests and for the qualitative discovery using PCR methods
- Participants: Name, organisation, department, job title, and country
- Organisation type: Clinics/hospitals, Government bodies, large international companies, research institutes, small and medium sized companies, universities and veterinary centres.
- Fields: Biotechnology, chemicals, clinical or hospital, defence, energy, environmental, food and drink, forensics, geology, government, healthcare, natural products, pharmaceuticals, research institutes, security and universities.
- Purpose: Purposes or reasons for using PCR across 16 major fields previously indicated. As the purposes or reasons differ with field, each was considered individually and presented to appropriate study participants. As an example, the potential reasons for using PCR in clinics and hospitals were clinical research, routine diagnostics, routine screening, clinical trials, treatment monitoring, diagnostics research, disease research, drug R&D, drug targets, pathology, toxicology or other [please contact Biopharm Reports if you require the full (16) industry-specific listings].
- Therapeutic areas: Use of PCR in 22 therapeutic areas, namely, arthritis, autoimmune diseases, bone metabolism, cancer, cardiovascular, central nervous system, dermatology, endocrine, gastrointestinal, genito-urinary system, haematology, infections, inflammation, metabolic disorders, musculoskeletal disorders, nutrition, obstetrics, and gynaecology, ophthalmology, pain, respiratory, skin, other or not applicable.
- Study samples: Study sample types analysed by PCR namely animal tissues, cell isolates, cells, cerebrospinal fluid, genetic material, human tissues, In-vitro biological solutions, microbiological materials, pathology samples, plasma, saliva, serum, urine, whole blood or other.
- Sample Preparation: The use of sample preparation methods for PCR studies, namely automated sample preparation, solid-Phase extraction (SPE), liquid-liquid extraction (LLE), size exclusion, organic solvent precipitation, direct injection, dialysis, affinity methods, Filtration and Other.
- Current PCR Techniques: Current use of more than 30 PCR techniques, including Allele-specific PCR, Assembly PCR (Polymerase Cycling Assembly, PCA), Asymmetric PCR (A PCR), Colony PCR, Degenerate Oligonucleotide PCR (DOP-PCR), Helicase-dependent amplification (HDA), Hot start PCR, In-Silico PCR, Intersequence-specific PCR (ISSR), Inverse PCR, Ligation-Mediated PCR, Long PCR, Loop-mediated isothermal amplification (LAMP), Methylation-Specific PCR (MSP), Miniprimer PCR, Multiplex Ligation-Dependent Probe Amplification (MLPA), Multiplex-PCR, Nested PCR, Overlap-Extension PCR ( Splicing by overlap extension, SOE), PAN-AC (Single Reaction Real Time PCR), PCR array, Quantitative PCR (qPCR), Reverse Transcription PCR (RT-PCR), Single Specific Primer-Polymerase Chain Reaction (SSP-PCR), Solid Phase PCR, Stepdown PCR, Taqman, Temporal Temperature Gradient Gel Electrophoresis (PCR-TTGE), Thermal Asymmetric Interlaced PCR (TAIL-PCR), Touchdown PCR, Universal Fast Walking or other.
- Future PCR Techniques: Anticipated use of more than 30 PCR techniques (indicated previously) over the next three years.
- Current PCR applications: Current use of more than 12 leading PCR applications including Cell-free DNA mutations, Cloning, Disease detection, Gene expression (mRNA), Gene mutations and alterations, Generating genetic probes, Genetic mapping, Genetic material amplification, Genetic sequencing, MicroRNA quantification, Pathogen detection/identification, Tissue typing and other.
- Future PCR applications: Anticipated use of more than 12 leading PCR applications (indicated previously) over the next three years
- Current Company suppliers: Current supplies of PCR and related systems from more than 25 companies
- Future Company suppliers: Future anticipated PCR supplies from more than 25 companies over the next three years
- Preferred Companies: Preferred Company in the PCR field.
- Preferred Products: Preferred product from the preferred Company
- Strengths: The strengths of the preferred product in the PCR field
- Weaknesses: The weaknesses of the preferred product in the PCR field
- Bioinformatics software: preferred bioinformatics software, used in PCR studies.
- Disease biomarkers: The use of PCR for the study of disease biomarkers (options yes or no).
- Main disease biomarkers: The types of biomarkers studied using PCR, namely gene variations (mutations/polymorphisms), DNA methylation, gene copy number, gene expression, SNPs, mRNA, MicroRNA or other.
- Disease biomarker utility: The use of disease biomarkers studied using PCR in terms of their clinical utility, where the options are disease prognosis, disease susceptibility or risk, disease stage or severity, drug discovery, early detection of disease, clinical trial endpoint, guidance of treatment, response to therapy, safety or toxicity factors or other.
- Challenges: The molecular type or parameter that presents the greatest technical challenge (qualitatively or quantitatively) in PCR, including sample type and PCR method used.
- Main reasons: The main technical challenges relating to the measurement of the molecular type or parameter referred to previously, using the PCR method indicated.
- Required innovation: The areas where innovation is most required (on a scale of 1-10) in PCR, where the options are sample preparation, ancillary techniques, PCR (qualitative) selectivity, PCR (quantitative) sensitivity, PCR reproducibility, PCR qualitative/quantitative capability, PCR robustness (ruggedness), detection methods, automation, speed or sample throughput, specialist data control systems, specialist bioinformatics systems or other.
- Recent innovations: The most important innovations in the use of PCR over the last three years.
- Future innovation: The most important anticipated innovations in the PCR field, over the next three years.
- Current financial budgets: Current annual financial budgets for PCR studies.
- Current budget breakdown: Budget breakdown relating to the use of PCR, in the areas of consumables, system control software, specialist bioinformatics software, PCR instruments, sample preparation and related instrumentation, ancillary systems/instrumentation, general overheads, staff salaries and other
- Future budget breakdown: The anticipated budget breakdown relating to the use of PCR, in the areas consumables, system control software, specialist bioinformatics software, PCR instruments, sample preparation and related instrumentation, ancillary systems/instrumentation, general overheads, staff salaries and other
- Future financial budgets: Anticipated changes (percentage increases or decrease) over the next three years, relating to their PCR activities
- Consumables: Top three consumables, associated with PCR activities
- Quality Control guidelines: Adherence to established quality control guidelines or procedures, relating to the conduct of PCR studies.

Chapter 1 Introduction

Chapter 2 Study Participants

2.1 This Chapter
2.2 Countries
2.3 Regions
2.4 Organisation Types
2.5 Fields
2.6 PCR Types
2.7 Participants
2.8 Discussion

Figure 2.1 Countries of individuals who participated in PCR 2012
Figure 2.2 Global regions of individuals who participated in PCR 2012.
Figure 2.3 Organisation types of individuals who participated in PCR 2012
Figure 2.4 Fields of individuals who participated in PCR 2012
Table 2.1 Countries of individuals who participated in PCR 2012
Table 2.2 Global regions of individuals who participated in PCR 2012
Table 2.3 Organisation types of individuals who participated in PCR 2012

Chapter 3 PCR Techniques

3.1 This Chapter
3.2 Current Techniques
3.3 Future Techniques
3.4 Discussion

Figure 3.1 Top ten currently used PCR techniques, indicated by individuals who participated in PCR 2012
Table 3.1 Currently used PCR techniques, indicated by individuals who participated in PCR 2012
Figure 3.2 Other currently used PCR techniques, indicated by individuals who participated in PCR 2012
Table 3.2 Other currently used PCR techniques, indicated by individuals who participated in PCR 2012
Figure 3.3 Top ten PCR techniques that end-users anticipate they will be using over the next three years (2012 to 2015), indicated by individuals who participated in PCR 2012
Table 3.3 PCR techniques that end-users anticipate they will be using over the next three years (2012 to 2015), indicated by individuals who participated in PCR 2012
Figure 3.4 Other PCR techniques that end-users anticipate they will be using over the next three years (2012 to 2015), indicated by individuals who participated in PCR 2012
Table 3.4 Other PCR techniques that end-users anticipate they will be using over the next three years (2012 to 2015), indicated by individuals who participated PCR 2012

Chapter 4 PCR Applications

4.1 This Chapter
4.2 Current Applications
4.3 Future Applications
4.4 Discussion

Figure 4.1 Top ten currently used PCR applications, indicated by individuals who participated in PCR 2012
Table 4.1 Currently used PCR applications, indicated by individuals who participated in PCR 2012
Figure 4.2 Other currently used PCR applications, indicated by individuals who participated in PCR 2012
Table 4.2 Other currently used PCR applications, indicated by individuals who participated in PCR 2012
Figure 4.3 Top ten PCR applications that end-users anticipate they will be using over the next three years (2012 to 2015), indicated by individuals who participated in PCR 2012
Table 4.3 PCR applications that end-users anticipate they will be using over the next three years (2012 to 2015), indicated by individuals who participated in PCR 2012
Figure 4.4 Other PCR applications that end-users anticipate they will be using over the next three years (2012 to 2015), indicated by individuals who participated in PCR 2012
Table 4.4 Other PCR applications that end-users anticipate they will be using over the next three years (2012 to 2015), indicated by individuals who participated in PCR 2012

Chapter 5 Companies

5.1 This Chapter
5.2 Current Companies
5.3 Future Companies
5.4 Discussion

Figure 5.1 Top ten PCR company suppliers, currently used by individuals who participated in PCR 2012
Table 5.1 PCR company suppliers, currently used by individuals who participated in PCR 2012
Figure 5.2 Other PCR company suppliers, currently used by individuals who participated in PCR 2012
Table 5.2 Other PCR company suppliers, currently used by individuals who participated in PCR 2012
Figure 5.3 Top ten PCR company suppliers that end-users anticipate they will be using over the next three years (2012 to 2015), indicated by individuals who participated in PCR 2012
Table 5.3 PCR company suppliers that end-users anticipate they will be using over the next three years (2012 to 2015), indicated by individuals who participated in PCR 2012
Figure 5.4 Other PCR company suppliers that end-users anticipate they will be using over the next three years (2012 to 2015), indicated by individuals who participated in PCR 2012
Table 5.4 Other PCR company suppliers that end-users anticipate they will be using over the next three years (2012 to 2015), indicated by individuals who participated in PCR 2012

Chapter 6 Preferred Companies and Products

6.1 This Chapter
6.2 Current Methods
6.3 Future Methods
6.4 Strengths
6.5 Weaknesses
6.6 Discussion

Figure 6.1 Top ten preferred suppliers in the PCR field, indicated by individuals who participated in PCR 2012
Table 6.1 Preferred suppliers in the PCR field, indicated by individuals who participated in PCR 2012
Figure 6.2 Other preferred suppliers in the PCR field, indicated by individuals who participated in PCR 2012
Table 6.2 Other preferred suppliers in the PCR field, indicated by individuals who participated in PCR 2012
Figure 6.3 Top ten preferred products in the PCR field, indicated by individuals who participated in PCR 2012
Table 6.3 Preferred products in the PCR field, indicated by individuals who participated in PCR 2012
Figure 6.4 Other preferred products in the PCR field, indicated by individuals who participated in PCR 2012
Table 6.4 Other Top preferred products in the PCR field, indicated by individuals who participated in PCR 2012
Figure 6.5 Top ten strengths of preferred products in the PCR field, indicated by individuals who participated in PCR 2012
Table 6.5 Strengths of preferred products in the PCR field, indicated by individuals who participated in PCR 2012
Figure 6.6 Other strengths of preferred products in the PCR field, indicated by individuals who participated in PCR 2012
Table 6.6 Other strengths of preferred products in the PCR field, indicated by individuals who participated in PCR 2012
Figure 6.7 Top ten weaknesses of preferred products in the PCR field, indicated by individuals who participated in PCR 2012
Table 6.7 Weaknesses of preferred products in the PCR field, indicated by individuals who participated in PCR 2012
Figure 6.8 Other weaknesses of preferred products in the PCR field, indicated by individuals who participated in PCR 2012
Table 6.8 Other weaknesses of preferred products in the PCR field, indicated by individuals who participated in PCR 2012

Chapter 7 PCR Expenditure and Budgets

7.1 This Chapter
7.2 Financial budget
7.3 Future Methods
7.4 Strengths
7.5 Weaknesses
7.6 Discussion

Figure 7.1 Annual financial budgets for PCR studies, indicated by individuals who participated in PCR 2012
Table 7.1 Annual financial budgets for PCR studies, indicated by individuals who participated in PCR 2012
Figure 7.2 The breakdown of current financial budgets for PCR studies, indicated by individuals who participated in PCR 2012
Table 7.2 The breakdown of current financial budgets for PCR studies, indicated by individuals who participated in PCR 2012
Figure 7.3 The anticipated future breakdown of financial budgets (over the next three years, 2012 to 2015) for PCR studies, indicated by individuals who participated in PCR 2012
Table 7.3 The anticipated future breakdown of financial budgets (over the next three years, 2012 to 2015) for PCR studies, indicated by individuals who participated in PCR 2012

Chapter 8 Purpose of PCR Use

8.1 This Chapter
8.2 Purpose
8.3 Discussion

Figure 8.1 Top ten reasons for using PCR in the biotechnology industry, indicated by individuals who participated in PCR 2012
Figure 8.2 Top ten reasons for using PCR in the Chemicals industry, indicated by individuals who participated in PCR 2012
Figure 8.3 Top ten reasons for using PCR in clinics or hospitals, indicated by individuals who participated in PCR 2012
Figure 8.4 Top ten reasons for using PCR in the environmental industry, indicated by individuals who participated in PCR 2012
Figure 8.5 Top ten reasons for using PCR in the food and drink industry, indicated by individuals who participated in PCR 2012
Figure 8.6 Top ten reasons for using PCR in the forensics industry, indicated by individuals who participated in PCR 2012
Figure 8.7 Top ten reasons for using PCR in the Government organisations, indicated by individuals who participated in PCR 2012
Figure 8.8 Top ten reasons for using PCR in the healthcare industry, indicated by individuals who participated in PCR 2012
Figure 8.9 Top ten reasons for using PCR in the pharmaceutical industry, indicated by individuals who participated in PCR 2012
Figure 8.10 Top ten reasons for using PCR in research institutes, indicated by individuals who participated in PCR 2012
Figure 8.11 Top ten reasons for using PCR in universities, indicated by individuals who participated in PCR 2012

Chapter 9 Samples

9.1 This Chapter
9.2 Purpose
9.3 Discussion

Figure 9.1 Top ten sample types analysed using DNA PCR, indicated by individuals who participated in PCR 2012
Table 9.1 Sample types analysed using PCR, indicated by individuals who participated in PCR 2012

Chapter 10 Sample Preparation

10.1 This Chapter
10.2 Sample Preparation
10.3 Discussion

Figure 10.1 Top sample preparation methods of DNA PCR users who participated in PCR 2012
Table 10.1 Sample preparation methods of PCR users who participated in PCR 2012
Figure 10.2 Other sample preparation methods of DNA PCR users who participated in PCR 2012
Table 10.2 Other sample preparation methods of DNA PCR users who participated in PCR 2012

Chapter 11 Therapeutic Areas

11.1 This Chapter
11.2 Therapeutic Areas
11.3 Discussion

Figure 11.1 Top ten therapeutic areas of PCR users who participated in PCR 2012
Table 11.1 Therapeutic areas of PCR users who participated in PCR 2012
Figure 11.2 Other therapeutic areas of PCR users who participated in PCR 2012
Table 11.2 Other therapeutic areas of PCR users who participated in PCR 2012

Chapter 12 Disease Biomarkers

12.1 This Chapter
12.2 Use of PCR
12.3 Biomarker Types
12.4 Clinical Utility
12.5 Discussion

Figure 12.1 The use of PCR for the study of disease biomarkers, indicated by individuals who participated in PCR 2012
Figure 12.2 Principal disease biomarkers studied using PCR, indicated by individuals who participated in PCR 2012
Table 12.1 Other disease biomarkers studied using PCR, indicated by individuals who participated in PCR 2012
Figure 12.3 Clinical utilities of disease biomarkers studied using PCR, indicated by individuals who participated in PCR 2012
Table 12.2 Other clinical utilities of disease biomarkers studied using PCR, indicated by individuals who participated in PCR 2012

Chapter 13 Bioinformatics Software

13.1 This Chapter
13.2 Bioinformatics Software
13.3 Discussion

Figure 13.1 Top ten bioinformatics software system used for PCR, indicated by users who participated in PCR 2012
Table 13.1 Bioinformatics software system used for DNA PCR, indicated by users who participated in PCR 2012
Figure 13.2 Other bioinformatics software system used for PCR, indicated by users who participated in PCR 2012
Table 13.2 Other bioinformatics software system used for PCR, indicated by users who participated in PCR 2012

Chapter 14 Challenging Applications

14.1 This Chapter
14.2 Most challenging Molecules
14.3 Most challenging sample types (matrices)
14.4 PCR methods used
14.5 Underlying reasons
14.6 Discussion

Figure 14.1 The most challenging molecules studies using PCR, indicated by users who participated in PCR 2012
Table 14.1 The most challenging molecules studies using PCR, indicated by users who participated in PCR 2012
Figure 14.2 The most challenging sample types (matrices) studies using PCR, indicated by users who participated in PCR 2012
Table 14.2 The most challenging sample types (matrices) studies using PCR, indicated by users who participated in PCR 2012
Figure 14.3 Top ten PCRs methods used with the most challenging molecules studies using PCR, indicated by users who participated in PCR 2012
Table 14.3 PCRs methods used with the most challenging molecules studies using PCR, indicated by users who participated in PCR 2012
Figure 14.4 Top ten underlying reasons for the challenges encountered using PCR analysis, indicated by users who participated in PCR 2012
Table 14.4 Underlying reasons for the challenges encountered using PCR analysis, indicated by users who participated in PCR 2012

Chapter 15 Innovation

15.1 This Chapter
15.2 Required Innovation
15.3 Recent Innovation
15.4 Future Innovation
15.5 Discussion

Figure 15.1 Top ten most required areas of innovation in PCR, indicated by individuals who participated in PCR 2012
Table 15.1 Most required areas of innovation in PCR, indicated by individuals who participated in PCR 2012
Figure 15.2 Other required areas of innovation in PCR, indicated by individuals who participated in PCR 2012
Table 15.2 Other required areas of innovation in PCR, indicated by individuals who participated in PCR 2012
Figure 15.3 Top ten recent innovations (in the last three years) in PCR, indicated by individuals who participated in PCR 2012
Table 15.3 Recent innovations (in the last three years) in PCR, indicated by individuals who participated in PCR 2012
Figure 15.4 Top ten future anticipated innovations (in the next three years) in PCR, indicated by individuals who participated in PCR 2012
Table 15.4 Future anticipated innovations (in the next three years) in PCR, indicated by individuals who participated in PCR 2012

Chapter 16 Quality Control

16.1 This Chapter
16.2 Quality Control
16.3 Future Innovation
16.4 Discussion

Figure 16.1 Top ten most commonly used quality control guidelines or procedures used in PCR analysis, indicated by individuals who participated in PCR 2012
Table 16.1 Quality control guidelines or procedures used in PCR analysis, indicated by individuals who participated in PCR 2012

Chapter 17 Discussion

Appendix 1





To order this report:
Genomics Industry: PCR 2013: A Focus on Sales Growth

__________________________

Contact Clare: clare@reportlinker.com
US:(339) 368 6001
Intl:+1 339 368 6001

SOURCE Reportlinker